Announcements Trials

Browse Landscape

Phase

Phase 2 25 Phase 1 11 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

INDUSTRY 5 OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 250 Radiotherapy 172 pembrolizumab 155 Carboplatin 147 Gemcitabine 139 Nivolumab 135 Paclitaxel 129 Dexamethasone 119 Cisplatin 118 fludarabine 115 Rituximab 104 Lenalidomide 103 Bevacizumab 99 Docetaxel 97 Capecitabine 97 fludarabine phosphate 92 Temozolomide 89 Cytarabine 89 Oxaliplatin 87 Etoposide 82 Filgrastim 77 Irinotecan 73 Doxorubicin 73 venetoclax 70 Peripheral Blood Stem Cell Transplantation 68 Fluorouracil 68 Radiosurgery 66 Melphalan 66 Everolimus 66 Bortezomib 66

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × Crizotinib × Clear all

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡